ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
ExcelFemale
HRT in Women
Pharmacotherapy for the treatment of vaginal atrophy
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 142770" data-attributes="member: 13851"><p><strong>ABSTRACT </strong></p><p><strong></strong></p><p><strong><span style="color: rgb(184, 49, 47)">Introduction: </span></strong><em>Despite its frequency, recognition and therapy of vulvovaginal atrophy (VVA) remain suboptimal. Wet mount microscopy, or vaginal pH as a proxy, allows VVA diagnosis in menopause, but also in young contraception users, after breast cancer, or postpartum. Intravaginal low-dose estrogen product is the main therapy. Ultra-low-dose vaginal estriol is safe and sufficient in most cases, even in breast cancer patients, while hyaluronic acid can help women who cannot or do not want to use hormones.</em></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Areas covered: </span></strong><em>The authors provide an overview of the current pharmaceutical treatment for vulvovaginal atrophy and provide their expert opinions on its future treatment.</em></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Expert opinion:</span></strong> <em>The basis of good treatment is a correct and complete diagnosis, using a microscope to study the maturity index of the vaginal fluid. <strong>A minimal dose of estriol intravaginally with or without lactobacilli is elegant, cheap, and can safely be used after breast cancer and a history of thromboembolic disease.</strong> Laser therapy requires validation and safety data, as it can potentially cause vaginal fibrosis and stenosis, and safer and cheaper alternatives are available.</em></p><p></p><p></p><p></p><p></p><p><strong>Article highlights </strong></p><p></p><p>●<strong><span style="color: rgb(184, 49, 47)"><em> Despite its frequency, vulvovaginal atrophy (VVA, part of GenitoUrinary Syndrome of Menopause) is underdiagnosed and undertreated, but a proper and complete diagnosis is essential for designing a good therapy and follow-up</em></span></strong></p><p></p><p>● <strong><span style="color: rgb(184, 49, 47)"><em>Although vaginal pH measurement can be used as a proxy, wet mount microscopy of vaginal fluid is superior to diagnose VVA by calculating the vaginal epithelial cell maturity index, but also to exclude infections and inflammation </em></span></strong></p><p></p><p>● <strong><span style="color: rgb(184, 49, 47)"><em>Local estrogens are the cornerstone of treatment, while systemic estrogens are reserved for patients with more menopausal symptoms. Although any type of locally applied estrogen is efficient, synthetic as well as biological, the safest and lowest dose should be used </em></span></strong></p><p></p><p>● <strong><span style="color: rgb(184, 49, 47)"><em>Novel hormonal therapies, such as dehydroepiandrosterone sulfate, ospemifene, estretol, are efficient, but their risks of complications like breast cancer and thromboembolism require further studies</em></span></strong></p><p></p><p>● <span style="color: rgb(184, 49, 47)"><strong><em>Women with contraindications for hormonal use such as breast cancer or previous thromboembolism should be tried on nonhormonal therapies, such as hyaluronic acid but if insufficient, use of ultralow-dose of locally applied estriol with or without lactobacilli can be a safe alternative </em></strong></span></p><p></p><p>● <strong><span style="color: rgb(184, 49, 47)"><em>Mechanical therapies like applying radiofrequency or laser waves to the vagina lack proper randomized studies comparing their efficacy to standard estrogen therapy, and proving their safety to prevent later scarring and stenosis of the vagina. This box summarizes key points contained in the article </em></span></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>5. Conclusion</strong></p><p></p><p><span style="color: rgb(184, 49, 47)"><em><strong>Several safe and efficient therapies are optional for the treatment of vulvovaginal atrophy, both hormonal and non-hormonal. </strong></em></span><strong><em>After trying nonhormonal moistening products, <u>a first-line therapy, intravaginal application of a low-dose estrogen product is recommended, unless more generalized menopausal symptoms demand systemic treatment (Figure 3)</u>. For women with contra-indications for estrogen therapy, nonhormonal therapy such as hyaluronic acid or laser therapy is possible, but also ultra-low-dose of estriol, with or without combined probiotic lactobacilli, seems safe and very efficacious. Laser therapy cannot be recommended until randomized studies prove its efficacy and safety, especially in the long term.</em></strong></p></blockquote><p></p>
[QUOTE="madman, post: 142770, member: 13851"] [B]ABSTRACT [COLOR=rgb(184, 49, 47)]Introduction: [/COLOR][/B][I]Despite its frequency, recognition and therapy of vulvovaginal atrophy (VVA) remain suboptimal. Wet mount microscopy, or vaginal pH as a proxy, allows VVA diagnosis in menopause, but also in young contraception users, after breast cancer, or postpartum. Intravaginal low-dose estrogen product is the main therapy. Ultra-low-dose vaginal estriol is safe and sufficient in most cases, even in breast cancer patients, while hyaluronic acid can help women who cannot or do not want to use hormones.[/I] [B][COLOR=rgb(184, 49, 47)]Areas covered: [/COLOR][/B][I]The authors provide an overview of the current pharmaceutical treatment for vulvovaginal atrophy and provide their expert opinions on its future treatment.[/I] [B][COLOR=rgb(184, 49, 47)]Expert opinion:[/COLOR][/B] [I]The basis of good treatment is a correct and complete diagnosis, using a microscope to study the maturity index of the vaginal fluid. [B]A minimal dose of estriol intravaginally with or without lactobacilli is elegant, cheap, and can safely be used after breast cancer and a history of thromboembolic disease.[/B] Laser therapy requires validation and safety data, as it can potentially cause vaginal fibrosis and stenosis, and safer and cheaper alternatives are available.[/I] [B]Article highlights [/B] ●[B][COLOR=rgb(184, 49, 47)][I] Despite its frequency, vulvovaginal atrophy (VVA, part of GenitoUrinary Syndrome of Menopause) is underdiagnosed and undertreated, but a proper and complete diagnosis is essential for designing a good therapy and follow-up[/I][/COLOR][/B] ● [B][COLOR=rgb(184, 49, 47)][I]Although vaginal pH measurement can be used as a proxy, wet mount microscopy of vaginal fluid is superior to diagnose VVA by calculating the vaginal epithelial cell maturity index, but also to exclude infections and inflammation [/I][/COLOR][/B] ●[I] [/I][B][COLOR=rgb(184, 49, 47)][I]Local estrogens are the cornerstone of treatment, while systemic estrogens are reserved for patients with more menopausal symptoms. Although any type of locally applied estrogen is efficient, synthetic as well as biological, the safest and lowest dose should be used [/I][/COLOR][/B] ● [B][COLOR=rgb(184, 49, 47)][I]Novel hormonal therapies, such as dehydroepiandrosterone sulfate, ospemifene, estretol, are efficient, but their risks of complications like breast cancer and thromboembolism require further studies[/I][/COLOR][/B] ● [COLOR=rgb(184, 49, 47)][B][I]Women with contraindications for hormonal use such as breast cancer or previous thromboembolism should be tried on nonhormonal therapies, such as hyaluronic acid but if insufficient, use of ultralow-dose of locally applied estriol with or without lactobacilli can be a safe alternative [/I][/B][/COLOR] ● [B][COLOR=rgb(184, 49, 47)][I]Mechanical therapies like applying radiofrequency or laser waves to the vagina lack proper randomized studies comparing their efficacy to standard estrogen therapy, and proving their safety to prevent later scarring and stenosis of the vagina. This box summarizes key points contained in the article [/I][/COLOR] 5. Conclusion[/B] [COLOR=rgb(184, 49, 47)][I][B]Several safe and efficient therapies are optional for the treatment of vulvovaginal atrophy, both hormonal and non-hormonal. [/B][/I][/COLOR][B][I]After trying nonhormonal moistening products, [U]a first-line therapy, intravaginal application of a low-dose estrogen product is recommended, unless more generalized menopausal symptoms demand systemic treatment (Figure 3)[/U]. For women with contra-indications for estrogen therapy, nonhormonal therapy such as hyaluronic acid or laser therapy is possible, but also ultra-low-dose of estriol, with or without combined probiotic lactobacilli, seems safe and very efficacious. Laser therapy cannot be recommended until randomized studies prove its efficacy and safety, especially in the long term.[/I][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
ExcelFemale
HRT in Women
Pharmacotherapy for the treatment of vaginal atrophy
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top